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Abstract
Background: The Inflammasomes are multi-protein complexes that regulate caspase-1 activation and the production of the
pro-inflammatory cytokine IL-1b. Previous studies identified a class of diarylsulfonylurea containing compounds called
Cytokine Release Inhibitory Drugs (CRIDs) that inhibited the post-translational processing of IL-1b. Further work identified
Glutathione S-Transferase Omega 1 (GSTO1) as a possible target of these CRIDs. This study aimed to investigate the
mechanism of the inhibitory activity of the CRID CP-456,773 (termed CRID3) in light of recent advances in the area of
inflammasome activation, and to clarify the potential role of GSTO1 in the regulation of IL-1b production.
Methodology and Results: In murine bone marrow derived macrophages, CRID3 inhibited IL-1b secretion and caspase 1
processing in response to stimulation of NLRP3 and AIM2 but not NLRC4. CRID3 also prevented AIM2 dependent pyroptosis
in contrast to the NLRP3 inhibitors glyburide and parthenolide, which do not inhibit AIM2 activation. Confocal microscopy
and Western blotting assays indicated that CRID3 inhibited the formation of ASC complexes or ‘specks’ in response to
NLRP3 and AIM2 stimulation. Co-immunoprecipitation assays show that GSTO1 interacted with ASC.
Significance: These results identify CRID3 as a novel inhibitor of the NLRP3 and AIM2 inflammasomes and provide an
insight into the mechanism of action of this small molecule. In addition GSTO1 may be a component of the inflammasome
that is required for ASC complex formation.
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Introduction
The production of the pro-inflammatory cytokine interleukin
(IL)-1b is a highly regulated process. An initial signal through the
activation of pattern recognition receptors such as Toll-like
receptors (TLRs) induces pro-IL-1b mRNA synthesis. Pro-IL-1b
is biologically inactive and requires processing to generate the
active 17 kilodalton (kDa) form that is secreted. Pro-IL-1b can be
processed by caspase-1 which itself requires processing to form the
active enzyme. The activation of caspase-1 is mediated by high
molecular weight protein complexes termed inflammasomes [1,2].
In addition to processing IL-1b and the related IL-1 family
cytokine IL-18, caspase-1 also plays a role in unconventional
protein secretion [3] and mediates a form of cell death called
pyroptosis [4].
The Nod-like receptor protein NLRP3 forms the prototypical
inflammasome by interacting with the adapter molecule apoptosis-
associated speck-like protein containing a CARD (ASC) via its
Pyrin domain (PYD). The caspase activation and recruitment
domain (CARD) of ASC in turn binds the CARD domain of
caspase-1 [4,5]. NLRP3 can be activated in response to a highly
diverse range of pathogen, environmental and endogenously
derived molecules. Danger molecules such as ATP, pore forming
toxins such as nigericin [6], particulates such as monosodium urate
crystals [7] and fibrils such as islet amyloid polypeptide [8] are all
sensed by NLRP3. NLRP3 is not directly activated but appears to
sense an intermediate process or cellular perturbation caused by
these molecules. These may include potassium efflux, the release of
lysosomal proteases and the generation of reactive oxygen species
[9]. NLRP3 protein expression levels are also a limiting step in
inflammasome activation. NLRP3 thus requires induction or
priming by TLR, NLR, IL-1 or TNFa stimulation [10].
Other NLR proteins such as NLRP1 and NLRC4 also form
inflammasomes. NLRC4 senses bacterial flagellin and the rod
protein from the type III secretion system apparatus of Gram-
negative bacteria. It requires another NLR family member either
NAIP5 or NAIP2 to detect its ligands [11,12]. Absent in
melanoma-2 (AIM2) is a non-NLR protein that is also capable
of forming an inflammasome. AIM2 is a member of the PYHIN
protein family that contain PYD domains and Hematopoietic
expression, IFN-inducible, nuclear localisation (HIN) domains
[13]. AIM2 recognises and directly binds cytosolic dsDNA via its
HIN domain and recruits ASC to activate caspase-1. AIM2 is a
broad sensor of dsDNA as it recognises viral, bacterial,
mammalian and synthetic dsDNA [14,15,16,17].
In a screen for inhibitors of IL-1b production a novel class of
sulfonylurea containing compounds were identified. These so-
called cytokine release inhibitory drugs or CRIDs (CP-424,174
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29539and CP-412,245) inhibited the post-translational processing and
secretion of IL-1b in response to LPS and ATP in human
monocytes [18]. Further studies identified glutathione-S-transfer-
ase omega 1 (GSTO1) as a possible target for CRIDs [19].
The discovery of CRIDs predates the discovery of the
inflammasomes. In this report we sought to characterise the
inhibitory activity of the CRID CP-456,773 (termed CRID3)
against multiple inflammasomes. We found that CRID3 inhibited
both NLRP3 and AIM2 inflammasomes by preventing ASC
oligomerisation. In addition GSTO1 was found to associate with
ASC suggesting that it might play a role in inflammasome
signalling and could indeed be a target of CRID3.
Results
CRID3 inhibits NLRP3 dependent IL-1b processing
The effect of CRID3 on the NLRP3 inflammasome was
examined in bone marrow derived macrophages (BMDM). As
shown in Figure 1A treatment with CRID3 (5–100 mM) dose
dependently inhibited the amount of IL-1b produced by BMDM
stimulated with lipopolysaccharide (LPS) and the NLRP3 activator
ATP, with 50 mM having an optimum effect. The inhibition of IL-
1b secretion was specific as CRID3 did not inhibit TNFa secretion
from these cells (Figure 1B). In Figure 1C it was confirmed by
Western blotting that CRID3 prevented the ATP stimulated
processing of pro-IL-1b to the mature 17 kilodalton (kDa) form,
the effect being optimal at 50 mM (compare lanes 5–7 to lane 3). As
shown in Figure 1D pre-treatment with CRID3 did not affect the
induction of pro-IL-1b by LPS (compare lanes 4 and 5 to lane 3).
The AIM2 inflammasome is inhibited by CRID3
As CRID3 was found to inhibit NLRP3 dependent responses
we next tested its effect on the activation of other inflammasomes.
Figure 2A shows that CRID3 inhibits the release of IL-1b from
BMDM stimulated with LPS and the AIM2 activator synthetic
dsDNA analog Poly (dA:dT) in a concentration dependent
manner, optimum inhibition occurring at 50 mM. IL-1b secretion
was not affected by treatment with the NLRP3 inhibitor
glyburide [20] or parthenolide, which has also been shown to
inhibit NLRP3 [21]. Glyburide and parthenolide both inhibited
NLRP3 activation by LPS and ATP (data not shown). As shown
in Figure 2B the secretion of TNFa from these cells was not
significantly inhibited by CRID3 or glyburide, with parthenolide
having a partial inhibitory effect. In Figure 2C treatment with
CRID3 prevented the production of mature cleaved IL-1b and
also prevented the processing of pro-caspase-1 as determined by
detection of the p10 fragment in the supernatants. This effect was
specific to the processing of IL-1b and caspase-1 as the levels of
pro-IL-1b and pro-caspase-1 in the cell lysates were not
decreased by treatment with CRID3 (lanes 5 and 6 in each case
compared to lane 3).
In addition to cytokine processing AIM2 activation also leads to
a caspase-1 dependent form of cell death known as pyroptosis.
Figure 2D demonstrates that CRID3 prevents Poly (dA:dT)
induced cell death, the effect being evident from 30 mM. Neither
glyburide nor parthenolide inhibited this response. Figure 2E
demonstrates that Poly (dA:dT) stimulated caspase-1 activation is
also prevented in the presence of CRID3 (lane 4) but not glyburide
(lane 5) or parthenolide (lane 6).
Figure 1. CRID3 inhibits LPS and ATP induced IL-1b processing. Primary BMDM were stimulated with 10 ng/ml LPS for 3 h, treated with
CRID3 (5–100 mM) or DMSO in serum free media for 30 min followed by addition of 5 mM ATP for 1 h. Supernatants were analysed by ELISA for IL -1b
(A), TNFa (B) or by Western blotting for pro and mature IL-1b (C). (A) and (B) Cytokine level is expressed as a percentage of that released from control
treated cells, which ranged across all experiments from 521–1988 pg/ml for IL-1b and 104–211 pg/ml for TNFa. Data are expressed as mean 6 S.E.M
of five independent experiments each carried out in triplicate. (C) A representative blot from one of three independent experiments is shown. (D)
BMDM were treated with DMSO or CRID3 (25–50 mM) for 30 min and were then stimulated with 10 ng/ml LPS for 3 h. Protein samples were analysed
by Western blotting using anti-IL-1b and anti-b-actin antibodies. A representative blot from one of two independent experiments is shown.
doi:10.1371/journal.pone.0029539.g001
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The effect of CRID3 on the activation of the NLRC4
inflammasome was also tested. A previous report showed that in
response to infection with Salmonella typhimurium at early time points
IL-1b secretion and cell death are NLRC4 dependent [22]. In
Figure 3 BMDM were primed with LPS prior to infection with S.
typhimurium. Pre-treatment with CRID3 or glyburide did not
significantly affect the levels of IL-1b (Figure 3A), TNFa
(Figure 3B) or LDH (Figure 3C) released by cells. In agreement
with the absence of an effect on IL-1b secretion or LDH release,
pre-treatment with CRID3 or glyburide did not affect caspase-1
activation (Figure 3D). The levels of IL-1b p17 and caspase-1 p10
detected in the supernatants of cells stimulated with LPS and S.
typhimurium was similar under every condition tested.
CRID3 prevents NLRP3 and AIM2 dependent ASC
oligomerisation
The activation of NLRP3 and AIM2 results in the recruitment
of ASC and the formation of large molecular weight oligomers
that in turn activate caspase-1. Figure 4A demonstrates that
stimulation of immortalized BMDM (I-BMDM) with LPS and
ATP caused the formation of ASC dimers and higher order
oligomers, which are detected in the cell pellet by Western blotting
(bottom panel, compare lanes 2 and 3). However, the pre-
treatment of cells with CRID3 and parthenolide before stimulation
with ATP prevented ASC oligomerisation (bottom panel, lanes 5
and 6), the production of IL-1b (top panel lanes 5 and 6) caspase-1
activation (third panel, lanes 5 and 6). CRID3 and parthenolide
did not affect ASC expression, as seen in the cell lysates (fourth
panel). As shown in Figure 4B transfection of I-BMDM with Poly
(dA:dT) also resulted in the appearance of ASC dimers in cell
pellets (bottom panel, lane 2). CRID3 inhibited the activation of
caspase-1 (top panel, lane 4) and the formation of ASC oligomers
(bottom panel, lane 4) whereas parthenolide and glyburide had no
effect on either response (top and bottom panels, lanes 5 and 6).
An additional assay was also employed to examine the
activation of ASC oligomerisation by NLRP3 and AIM2. Murine
immortalized macrophages that stably express ASC-YFP were
used to analyse the formation of ASC oligomers or ‘specks’. As
shown in Figure 5A in unstimulated cells or cells treated with LPS
alone (Figure 5B) the YFP-ASC is diffuse throughout the cytosol of
Figure 2. CRID3 inhibits the AIM2 inflammasome. Primary BMDM were stimulated with 10 ng/ml LPS for 3 h, treated with CRID3 (10–50 mM),
200 mM glyburide, 10 mM parthenolide or DMSO control in serum free media for 1 h followed by transfection of 1 mg/ml Poly (dA:dT) for 4 h (A) and
(B) or overnight (C). Supernatants were analysed by ELISA for IL -1b (A) and TNFa (B). (A) and (B) Cytokine level is expressed as a percentage of that
released from control treated cells, which ranged across all experiments from 518–2347 pg/ml for IL-1b and 397–1136 pg/ml for TNFa. Data are
expressed as mean 6 S.E.M of four independent experiments each carried out in triplicate. In (C) concentrated supernatants and cell lysates were
analysed by Western blotting using anti-IL-1b, anti-caspase-1 and anti-b-actin antibodies. These results are representative of three independent
experiments. (D) and (E) Primary BMDM were treated with CRID3 (10–50 mM), 200 mM glyburide,10 mM parthenolide or DMSO in serum free media for
1 h followed transfection of 1 mg/ml Poly (dA:dT) for 6 h. Supernatants were analysed using an LDH cytotoxicity assay. The data shown represent
mean % LDH release 6 S.D. from triplicate determinations and are representative of three independent experiments. In (E) Concentrated
supernatants and cell lysates were analysed by Western blotting using anti-caspase-1 and anti-b-actin antibodies. These results are representative of
four independent experiments.
doi:10.1371/journal.pone.0029539.g002
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(Figure 5C, first row) or Poly (dA:dT) (Figure 5D, first row) the
YFP-ASC condenses into a large, bright, speck. Arrowheads are
included to indicate typical specks. CRID3 at 50 mM and 10 mM
parthenolide prevented the formation of specks in response to
stimulation with LPS and ATP (Figure 5C, second and third rows).
As shown in Figure 5D CRID3 (50 mM) also inhibited speck
formation in cells stimulated with LPS and Poly (dA:dT)
(Figure 5dD second row), whereas glyburide had no effect
(Figure 5D, third row).
GSTO1 interacts with ASC
Previous investigations into the target of the CRID compounds
had identified GSTO1 as the primary candidate for their target of
action [19]. As CRID3 inhibited both NLRP3 and AIM2
dependent responses it was investigated whether GSTO1 could
interact with components of the inflammasome. As shown in
Figure 6A ASC immunoprecipitated together with both endoge-
nous lane 7) and overexpressed GSTO1 (lane 8) in HEK293T
cells. Figure 6B shows that no interaction between NLRP3 and
GSTO1 could be detected (lanes 7 and 8).
Discussion
This study has identified CRID3 as an inhibitor of the NLRP3
and AIM2 inflammasomes but not the NLRC4 inflammasome.
CRID3 inhibited ASC oligomerisation. A previously identified
target of CRID3, GSTO1 was shown to interact with ASC
suggesting that it may be required for ASC function in the
inflammasome.
CRID3 dose dependently prevented IL-1b but not TNFa
secretion from BMDM stimulated with LPS and ATP. This result
is in line with previous studies on the effects of related CRID
compounds [18,19]. The decrease in IL-1b secretion was due to
inhibition of IL-1b processing as CRID3 did not have an effect on
pro-IL-1b induction. CRID3 was also found to inhibit the AIM2
inflammasome, preventing IL-1b secretion, caspase-1 activation
and cell death in response to AIM2 activation by Poly (dA:dT).
The other NLRP3 inhibitors glyburide and parthenolide had no
significant effect on AIM2 mediated responses pointing to
specificity in their actions. Juliana et al. [21] have shown that
parthenolide directly inhibits caspase-1 by alkylation of certain
cysteine residues. Our results disagree with this assertion as we did
not find that parthenolide inhibited caspase-1 in response to AIM2
stimulation. However, the previous study [21] did not test AIM2
activation so perhaps parthenolide only inhibits caspase-1 in
response to NLRP3 or NLRC4 activation. Importantly CRID3
did not affect NLRC4 mediated caspase-1 activation and IL-1b
secretion in response to S. typhimurium infection.
It was possible that CRID3 was targeting ASC, since ASC is
required for the function of the NLRP3 and AIM2 inflammasomes
but has a lesser role in the NLRC4 inflammasome. In both the
Western blotting and ASC-YFP fluorescence microscopy assays it
was found that pre-treatment with CRID3 prevented ASC
oligomerisation in response to stimulation with LPS and ATP or
Poly (dA:dT). In agreement with the effects seen previously on IL-
Figure 3. CRID3 and glyburide do not inhibit the NLRC4 inflammasome. Primary BMDM were stimulated with 10 ng/ml LPS for 3 h, treated
with CRID3 (10–50 mM), 200 mM glyburide or DMSO in serum free media for 30 min followed by infection with S. typhimurium (M.O.I 20) for 2 h.
Supernatants were analysed by ELISA for IL -1b (A) and TNFa (B) production or by LDH cytotoxicity assay (C). (A) and (B) cytokine level is expressed as
a percentage of that released from control treated cells, which ranged across all experiments from 534–3013 pg/ml for IL-1b and 1990–2746 pg/ml
for TNFa. (A), (B) and (C) data are expressed as mean 6 S.E.M of three independent experiments each carried out in triplicate. In (D) concentrated
supernatants and cell lysates were analysed by Western blotting using anti-IL-1b, anti-caspase-1 and anti-b-actin antibodies. These results are
representative of three independent experiments.
doi:10.1371/journal.pone.0029539.g003
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did not inhibit AIM2 dependent ASC oligomerisation.
ASC is indispensible for both NLRP3 and AIM2 inflammasome
formation. As CRID3 prevents ASC oligomerisation in response
to activation of both these molecules this would suggest that
CRID3 acts directly or at the level of ASC in these complexes.
The role of ASC in the NLRC4 inflammasome is less clear. The
caspase activation and recruitment domain (CARD) of NLRC4
can interact directly with caspase-1 but ASC facilitates more
efficient IL-1b secretion [1,23]. ASC does not play a role in
NLRC4 induced cell death as in vivo studies showed NLRC4
mediated pyroptosis, which is critical for S. typhimurium clearance
was independent of ASC [24]. CRID3 did not prevent S.
typhimurium induced cell death and thus does not inhibit NLRC4.
There may be a partial role for ASC in IL-1b induction in
response to NLRC4, since at early time points this response is
impaired in ASC deficient macrophages [22]. However we found
that CP- CRID3 had no effect on NLRC4 dependent IL-1b
secretion. This may be because ASC was not involved in the
particular conditions we tested or because CRID3 specifically
inhibits ASC on the NLRP3 and AIM2 pathways. From our ASC
assays however, it is clear that CRID3 can inhibit ASC activation
by NLRP3 and AIM2.
A previous study using affinity labelling and affinity binding
chromatography techniques had identified GSTO1 as the target of
CRID compounds [19]. GSTO are the most recently identified
and characterised class of cytosolic GSTs. GSTO1 is an unusual
GST as it contains an active site cysteine residue and displays little
activity with typical GST substrates. It does however have thiol
transferase activity that is characteristic of glutaredoxins [25]. An
initial possible mechanism of CRID3 inhibition could have been
through directly preventing caspase-1 activation. A previous study
has shown that caspase-1 could be inhibited by glutathionylation
of Cys397 and Cys362 during conditions of oxidative stress [26].
Thus it was possible that CRID3 could deglutathionylate caspase-
1. However, as CRID3 failed to inhibit NLRC4 activated caspase-
1 activation this suggested that CRID3 was not directly affecting
caspase-1. It has been suggested previously that related CRID
compounds were not direct caspase-1 inhibitors although the data
was not shown in the report [18]. The physiological role of
GSTO1 remains ill-defined although some studies have implicated
a role in drug resistance and the oxidative stress response [27,28].
Polymorphisms in GSTO1 were also shown to affect the risk of
developing sporadic Alzheimer’s disease [29].
We speculated that GSTO1 might interact with components of
the inflammasome. Co-immunoprecipitation experiments indicat-
ed that GSTO1 did not interact with NLRP3 but did interact with
ASC. GSTO1 is therefore a novel component of the NLRP3 and
AIM2 inflammasomes. How GSTO1 affects ASC is open to
speculation. As mentioned previously caspase-1 was shown to be
negatively regulated by glutathionylation [26], ASC may also
subject to this post-translational modification. There is an
emerging literature indicating that reversible glutathionylation of
proteins is a form of signal transduction analogous to protein
phosphorylation or ubiquitination.
Glutathionylation has been implicated in the regulation of
TNFa induced apoptosis through reversible glutathionylation of
caspase-3 [30]. While the glutathionylation of endothelial nitric
oxide synthase (eNOS) has been shown to regulate its function in
vasodilation [31]. There are also examples of GSTs as regulators
of cytokine signalling. GSTP regulates TNFa signalling by
associating with tumour-necrosis factor receptor-associated factor
Figure 4. CRID3 prevents NLRP3 and AIM2 stimulated ASC oligomerisation. (A) I-BMDM were stimulated with 10 ng/ml LPS for 3 h, were
treated with 50 mM CRID3, 10 mM parthenolide, DMSO or were left untreated in serum free media for 30 min followed by addition of 5 mM ATP for
1 h. (B) Cells were treated with with 50 mM CRID3, 200 mM glyburide,10 mM parthenolide, DMSO or were left untreated in serum free media for
30 min followed by transfection with 1 mg/ml Poly (dA:dT) for 5 h. Concentrated supernatants and cell lysates were analysed by Western blotting
using anti-IL-1b and/or anti-caspase-1 antibodies. The cell lysates were centrifuged at 330 x g for 10 min at 46C. The pellets were washed and
resuspended in PBS and then cross-linked by incubation with DSS for 30 min. The cross-linked pellets and cell lysates were analysed by Western
blotting with anti-ASC and anti-caspase-1 antibodies. The data shown are representative of two (A) and three (B) independent experiments.
doi:10.1371/journal.pone.0029539.g004
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signal regulating kinase 1 (ASK1). This activity of GSTP was
independent of its glutathione conjugating activity [32]. Perhaps
GSTO1 regulates the interaction of ASC with NLRP3 or AIM2 or
with other ASC molecules, with CRID3 interfering with this
interaction, preventing formation of the inflammasome protein
complex.
There is significant evidence that ASC regulates innate immune
responses separate to its role in the inflammasome. Studies on
ASC deficient mice have shown that ASC is required for the
induction of humoral immunity after vaccination with the MF59
adjuvant. ASC deficient mice had significantly reduced antigen
specific IgG responses, whereas caspase-1 and NLRP3 deficient
mice had normal responses [33]. In contrast to caspase-1 and
NLRP3 deficient mice, ASC deficient mice were completely
protected from the development of arthritis in a collagen induced
arthritis study. This was due to defective T cell activation by ASC
deficient dendritic cells [34]. ASC deficient mice were also more
protected than caspase-1 deficient mice from a mouse model of
multiple sclerosis (experimental autoimmune encephalitis or EAE)
[35]. An inhibitor of ASC such as CRID3 could therefore be an
effective treatment for these diseases. A recent study has also
defined an inflammasome independent role for ASC in the post-
transcriptional regulation of the guanine nucleotide exchange
factor Dock2. ASC deficient dendritic cells had very low Dock2
expression, which led to decreased Rac dependent actin
polymerization and consequently impaired antigen uptake and
chemotaxis [36]. As GSTO1 interacted with ASC but not NLRP3
it is possible that GSTO1 may also influence these non-
inflammasome related functions of ASC. Further studies on the
mechanism of ASC function in these settings may establish if
GSTO1 is required specifically or ubiquitously for ASC mediated
immune responses.
Given the role of IL-1b in diseases such as type 2 diabetes [8],
gout [7] and osteoarthritis [37], which all involve NLRP3, a small
molecule such as CRID3 could have promise therapeutically and
be an alternative to IL-1b biologics such as the anti-IL-1b
antibody Canakinumab and the IL-1 Trap Rilonacept. Future
work aims to elucidate the precise molecular target for CRID3.
Materials and Methods
Materials
Ultrapure rough LPS (from E. coli, serotype EH100) was
purchased from Alexis. Poly(deoxyadenylic-thymidylic) acid
sodium salt (Poly dA:dT) and adenosine 59-triphosphate disodium
salt hydrate (ATP) were purchased from Sigma-Aldrich. S.
typhimurium UK-1 strain was obtained from Dr. Sinead Corr
(Trinity College Dublin, Ireland). Glyburide was obtained from
Sigma-Aldrich. Parthenolide was purchased from Enzo Life
Sciences. CP-456,773 (CRID3) was from Amgen Inc., Thousand
Oaks, CA, USA. GeneJuiceH was purchased from Novagen.
Lipofectamine 2000
TM was from Invitrogen. Protein A/G Plus
agarose immunoprecipitation reagent was from Santa Cruz
Biotechnology. StrataClean
TM resin was from Agilent Technol-
ogies. TNF-a and IL-1b ELISA Duosets were purchased from
R&D Systems. CytoTox96H non-radioactive cytotoxicity assay
was from Promega.
Figure 5. CRID3 inhibits NLRP3 and AIM2 stimulated ASC speck formation. (A) ASC-YFP cells were left unstimulated, or were (B) stimulated
with 10 ng/ml LPS for 3 h. (C) Cells were stimulated with 10 ng/ml LPS for 3 h, treated with 50 mM CRID3 10 mM parthenolide or DMSO in serum free
media for 30 min followed by addition of 5 mM ATP for 1 h. In (D) cells were stimulated with 10 ng/ml LPS for 3 h, treated with 50 mM CRID3, 200 mM
glyburide or DMSO in serum free media for 40 min followed by transfection of 1 mg/ml Poly (dA:dT) for 2 h. Cells were viewed by live cell imaging, at
least four different images were taken of each dish of which a representative image is shown. These results are representative of three independent
experiments.
doi:10.1371/journal.pone.0029539.g005
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John Curtin School of medical research, Australian National
University, Australia. The pCI ASC-HA expression vector was a
gift from Dr. Kate Fitzgerald, University of Massachusetts, USA.
Empty vector pcDNA 3.1 myc-His was from Invitrogen. Myc-
caspase-1 and myc-NLRP3 were gifts from Prof. Dan Kastner,
National Institute of Arthritis and Musculoskeletal and Skin
Diseases, Bethesda, Maryland, USA. ASC antibody (AL177) was
from Enzo Life Sciences. Murine caspase-1 p10 (M-20) and c-Myc
(9E10) antibodies were obtained from Santa Cruz Biotechnology.
HA.11 antibody was from Covance. Murine IL-1b antibody was
from R&D Systems. Rabbit antiserum raised against recombinant
hGSTO1-1 was a gift from Prof. Philip Board, John Curtin School
of medical research, Australian National University, Australia. b-
actin, and anti-rabbit IgG were obtained from Sigma-Aldrich.
Cell culture
The immortalised BMDM were a kind gift from Prof. Douglas
Golenbock, University of Massachusetts, USA [38]. Stably
transfected ASC-FP macrophages were a kind gift from Dr. Eicke
Latz, University of Massachusetts, USA [39]. The human
embryonic kidney T cell line (HEK-293T) was purchased from
the European Cell Culture Collection. HEK293T, ASC-FP and I-
BMDM cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS)
and 1% penicillin/streptomycin (v/v). Bone marrow from
C57BL/6 mice was differentiated for 7 days in DMEM
supplemented with 10% fetal calf serum (FCS), 1% penicillin/
streptomycin (v/v) and M-CSF (20% (v/v) L929 mouse fibroblast




For cytokine measurements, BMDM were stimulated in
triplicate as indicated. Supernatants were removed and analysed
for IL-1b and TNF-a using enzyme-linked immunosorbent assay
(ELISA) kits according to the manufacturer’s instructions (R&D
Systems).
Western blotting
For Western blotting experiments BMDM were seeded in 12
or 6 well plates at 0.521610
6/ml. Cell lysates were prepared by
direct lysis in 5X Laemmli sample buffer. The protein content of
supernatants was concentrated using StrataClean
TM resin
according to the manufacturer’s instructions. The protein
samples were resolved on 12% or 15% SDS-PAGE gels and
transferred onto polyvinylidene diflouride (PVDF) membrane
using a wet transfer system. Membranes were blocked in 5% (w/
v) dried milk in TBS-T (50 mM Tris/HCL, pH 7.6, 150 mM
NaCl and 0.1% (v/v) Tween-20) for an hour at room
temperature (RT). The membranes were incubated with primary
antibody diluted 1 in 1000 in 5% (w/v) dried milk in TBS-T.
The membranes were then incubated with the appropriate horse
radish peroxidise conjugated secondary antibody diluted 1 in
2000 in 5% (w/v) dried milk in TBS-T for an hour before being
developed by enhanced chemiluminescence (ECL) according to
the manufacturer’s instructions (Cell Signaling Technology,
Inc.). Some membranes were stripped using Restore
TM PLUS
western blot stripping buffer according to the manufacturer’s
instructions (Thermo Fisher Scientific Inc.) before being re-
probed.
Cytotoxicity assay
A CytoTox96H non-radioactive cytotoxicity assay kit was used
according to the manufacturer’s instructions (Promega) to
determine lactate dehydrogenase (LDH) release from cells.
ASC complex isolation
2610
6 I-BMDM cells were seeded in each well of a 6 well plate.
The following day cells were stimulated with 10 ng/ml LPS for
3 hours before treatment with the indicated inhibitors or controls
for 30 mins followed by the addition of 5 mM ATP for 1 hour or
cells were pre-treated with inhibitors for 30 mins followed by
transfection of 1 mg/ml Poly (dA:dT) for 5 hrs. The supernatants
were removed, cells were rinsed in ice-cold PBS and 500 ml ice-
cold buffer (20 mM Hepes-KOH, pH 7.5, 150 mM KCL, 1%
NP-40 0.1 mM PMSF, 1 mg/ml leupeptin, 11.5 mg/ml aprotinin
and 1 mM sodium orthovanadate) was added. The cells were
removed using a cell scraper and transferred to microcentrifuge
tubes. Cells were lysed by shearing 10X through a 21 gauge
needle. 50 ml of lysate was removed for Western blot analysis. The
lysates were centrifuged at 330 x g for 10 min at 4uC. The pellets
were washed twice in 1 ml ice-cold PBS (centrifuged 330 x g for
3 min at 4uC) and resuspended in 500 ml PBS. 2 mm disuccini-
mydyl suberate (DSS) (from a fresh 100 mM stock prepared from
DSS equilibrated to RT and made up in dry DMSO) was added to
the re-suspended pellets, which were incubated at RT for 30 min
with rotation. The samples were then centrifuged at 330 x g for
10 min at 4uC. The supernatant was removed and the cross-linked
pellets were resuspended in 30 ml Laemmli sample buffer. The
samples were boiled for 5 min at 99uC and analysed by Western
blotting.
Figure 6. ASC but not NLRP3 immunoprecipitates with GSTO1.
HEK-293T cells were transfected with HA-ASC, Myc-NLRP3, GSTO1 or
empty vector plasmids as indicated. 48 hours post transfection cells
were lysed in low stringency lysis buffer. 50 ml of lysate was kept for
analysis while the remaining lysates were pre-cleared using 10 ml
Protein A/G beads for 30 min. The lysates were then incubated with
anti-GSTO1 antibody or rabbit IgG coupled to protein A/G beads for 3 h
at 4uC. Whole cell lysates and immunoprecipitation samples were
analysed by Western blotting using anti-Myc, anti-HA or anti-GSTO1
antibodies. The results presented are representative of two (B) and
three (A) independent experiments.
doi:10.1371/journal.pone.0029539.g006
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ASC-FP cells were seeded at 2610
5/ml the day prior to use in
experiments on 35 mm glass bottom culture dishes. Cells were
stimulated with 10 ng/ml LPS for 3 hours before treatment with
the indicated inhibitors or controls for 30–40 mins followed by the
addition of 5 mM ATP for 1 hour or transfection of 1 mg/ml Poly
(dA:dT) for 2 hrs. Imaging was performed on an Olympus
FluoView
TM FV1000 Microscope equipped with a temperature
and CO2 controlled chamber.
Co-immunoprecipitation assay
HEK293T cells were seeded at 2610
5 per ml. 24 hours later
cells were transfected with a total of 8 mg of the indicated plasmids
using GeneJuiceH. Cells were cultured for 36–48 hours prior to
harvesting in low stringency lysis buffer (50 mM Hepes pH 7.5,
100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA),
10% glycerol, 0.5% Nonidet P40 (NP-40), 1 mM phenylmethyl-
sulphonyl fluoride (PMSF), 1 mg/ml leupeptin, 11.5 mg/ml
aprotinin and 1 mM sodium orthovanadate] on ice for 15 min.
Lysates were centrifuged at 1610 x g for 10 min at 4uC. Lysates
were pre-cleared for 30 min with 10 ml Protein A/G Plus agarose
beads. Prior to incubation with lysates 1 mg of the relevant
antibodies was incubated with 25 ml Protein A/G Plus agarose
beads overnight. The lysates were then incubated with pre-
coupled antibodies/beads for 4 hrs rotating at 4uC. The lysates
and beads were centrifuged at 80 x g for 3 min at 4uC, the
supernatant was removed and the beads were washed 3 times in
1 ml of low stringency lysis buffer. The immune complexes were
eluted by the addition of 35 ml Laemmli sample buffer, and
analysed by SDS-PAGE and Western blotting.
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